Article Text

Download PDFPDF

LO-017 Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: results from the open-label Phase 1b/2 MISSION study
  1. Brad Rovin1,
  2. Amit Saxena2,
  3. Richard Leff3,
  4. Elaine Li4,
  5. Eunmi Park5 and
  6. Noreen Henig6
  1. 1Nephrology, The Ohio State University Wexner Medical Center, USA
  2. 2Rheumatology, NYU School of Medicine, USA
  3. 3Clinical Development, Kezar Life Sciences, USA
  4. 4Biometrics, Kezar Life Sciences, USA
  5. 5Medical Affairs, Kezar Life Sciences, USA
  6. 6Chief Medical Officer, Kezar Life Sciences, USA


Background Zetomipzomib is a first-in-class selective inhibitor of the immunoproteasome that offers anti-inflammatory properties without significant immunosuppression.1 2

Methods The MISSION study is a Phase 1b/2, open-label study to evaluate safety, tolerability, and exploratory efficacy of zetomipzomib in patients with active systemic lupus erythematosus (SLE) ± lupus nephritis (LN). The Phase 1b portion included multiple dose escalation cohorts to evaluate the safety and tolerability of zetomipzomib in patients with SLE ± LN. The Phase 2 portion studied patients with active LN (Class III/IV ± V) to assess the efficacy and safety of zetomipzomib. Study schematics and endpoints are detailed in figure 1.

Results In the Phase 1b portion (47 patients enrolled, 35 patients completed study), zetomipzomib demonstrated a favorable safety/tolerability profile and resulted in improvement across multiple exploratory disease activity measures (table 1) and biomarkers including anti-dsDNA.3 In the Phase 2 portion (21 patients enrolled, 17 patients completed study), patients receiving 24 weeks of zetomipzomib treatment demonstrated clinically meaningful renal responses, which were maintained or increased through Week 37 (12 weeks post-treatment; end of study [EOS]); table 1. Of the 17 patients, 14 patients reduced glucocorticoids to ≤10 mg/d as early as Week 13, which was maintained through the EOS. Treatment with zetomipzomib also improved key SLE disease activity scores and serologic biomarkers including anti-dsDNA, C3/C4 (table 1). An exploratory inflammatory biomarker, urinary CD163, also decreased, and this reduction was highly correlated with UPCR reduction (R²=0.8894). The most common adverse event (AE) was injection site reaction of mild to moderate severity (Grade ≤2). No serious/opportunistic infections or immune cell depletion were reported.

Conclusions In the MISSION study, treatment with zetomipzomib in SLE/LN patients reduced proteinuria and improved biomarkers of disease activity, with lowered glucocorticoid dosing and without serious/opportunistic infections. Zetomipzomib has the potential to be a steroid-sparing immunomodulatory therapy for patients with SLE/LN.

Abstract LO-017 Figure 1

MISSION Phase 1b/2 open-label study schematics and endpoints

Abstract LO-017 Table 1

Select exploratory efficacy outcomes in the MISSION study


  1. Kisselev AF, Groettrup M. Curr Opin Chem Bio. 2014;23(16–22).

  2. Parikh et al. 2022 ASN Kidney Week.

  3. Furie et al. 2021 EULAR Virtual Congress.

  • Lupus nephritis
  • zetomipzomib (KZR-616)
  • immunoproteasome

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.